Abstract
Myasthenia gravis (MG) may be associated with other autoimmune diseases, including primary biliary cirrhosis1 or primary sclerosing cholangitis (PSC)2, which may complicate or prohibit liver-toxic immunosuppression. Here we show that immunosuppression must be applied with caution, but it is effective over five years if the dosage is adapted to a tolerable amount […] Long-term, low-dose immunosuppression for myasthenia does not affect collateral, asymptomatic sclerosing cholangitis
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
